Ingrezza and Memory loss - a phase IV clinical study of FDA data

Summary:

Memory loss is reported as a side effect among people who take Ingrezza (valbenazine tosylate), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Seroquel, and have Tardive dyskinesia.

The phase IV clinical study analyzes which people have Memory loss when taking Ingrezza. It is created by eHealthMe based on reports of 23,655 people who have side effects when taking Ingrezza from the FDA, and is updated regularly.

What is Ingrezza?

Ingrezza has active ingredients of valbenazine tosylate. eHealthMe is studying from 23,666 Ingrezza users. Check the latest studies of Ingrezza.

What is Memory loss?

Memory loss is found to be associated with 2,728 drugs and 4,376 conditions by eHealthMe. Check the latest studies of Memory loss.

On Jul, 23, 2026

23,655 people reported to have side effects when taking Ingrezza.
Among them, 241 people (1.02%) have Memory loss.

Among these 241 people:

* Approximation only. Some reports may have incomplete information.

Do you take Ingrezza and have Memory loss?

- Check whether Memory loss is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Ingrezza:

Ingrezza (23,666 reports)

Memory loss treatments and more:

Memory loss (244,444 reports)

How severe was Memory loss and when was it recovered:

Memory loss in Ingrezza

Expand to all the drugs that have ingredients of valbenazine tosylate:

Memory loss and drugs with ingredients of valbenazine tosylate

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Ingrezza:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Memory loss:

Memory loss (2,728 drugs)

Browse all the conditions that are associated with Memory loss:

Memory loss (4,376 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on valbenazine tosylate (the active ingredients of Ingrezza) and Ingrezza (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.